Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00827697 · ClinicalTrials.gov registry record
A Validation Study for Detecting Chlamydia and Gonorrhea in Rectal Samples
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 399
- Enrollment target
NCT00827697: Completed study, sponsored by University of Pittsburgh.
NCT00827697 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 399 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00827697 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 399 participants
- Enrollment target
Study Summary
Our hypothesis is that nucleic acid amplification testing (NAAT) with the APTIMA Combo2 (AC2) will have greater sensitivity than culture in detecting Neisseria gonorrhoeae in rectal samples. We also hypothesize that AC2 will be equivalent to NAAT with the Becton Dickinson ProbeTec in detecting Chlamydia trachomatis and Neisseria gonorrhoeae in rectal samples.
Primary Outcome
Sensitivity and specificity of AC2 to ProbeTec and culture in detecting Neisseria gonorrhoeae in rectal samples
Interventions
- OTHER Gen-Probe APTIMA Combo2 (AC2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 399 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-03 |
What the finished NCT00827697 record still lists
NCT00827697 is an observational study that tracks outcomes without assigning an intervention. The registered 399 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Gen-Probe APTIMA Combo2 (AC2) is the first listed.
NCT00827697 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00827697 about?
NCT00827697 is a clinical study titled "A Validation Study for Detecting Chlamydia and Gonorrhea in Rectal Samples". Our hypothesis is that nucleic acid amplification testing (NAAT) with the APTIMA Combo2 (AC2) will have greater sensitivity than culture in detecting Neisseria gonorrhoeae in rectal samples. We also hypothesize that AC2 will be equivalent to NAAT with the Becton Dickinson ProbeTec in detecting Chlam...
What is the current status of trial NCT00827697?
This trial is currently completed. The enrollment target is 399 participants. The study started on 2009-05. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00827697?
The interventions under investigation include: Gen-Probe APTIMA Combo2 (AC2) (OTHER).
Who is sponsoring clinical trial NCT00827697?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03165734 · 399 participants · Phase 3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
- NCT05022862 · 399 participants · NA
Economic Incentives and vDOT for Latent Tuberculosis Infection
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia